Related Experiment Video
Updated: Jun 19, 2026
03:55
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
Management of Differentiated Thyroid Cancer
Laszlo Hegedüs1, Lori J Wirth2, R Michael Tuttle3
1Department of Endocrinology, Odense University Hospital, University of Southern Denmark, Odense.
The New England Journal of Medicine
|June 17, 2026
Summary
This study introduces a dynamic risk stratification framework for thyroid cancer management. It aids personalized treatment decisions by integrating clinical, molecular, and patient factors for better outcomes.
Area of Science:
- Oncology
- Endocrinology
- Medical Decision Making
Background:
- Thyroid cancer management requires dynamic risk stratification from nodule detection through follow-up.
- Current approaches integrate clinicopathological staging with molecular risk characterization for tailored plans.
- Management plans evolve based on disease natural history and treatment response.
Purpose of the Study:
- To present a clinical framework for therapeutic decision-making in thyroid cancer.
- To illustrate the application of this framework in diverse clinical scenarios.
- To facilitate informed consensus and personalized management recommendations.
Main Methods:
- Development of a clinical framework for risk-adapted thyroid cancer management.
- Integration of clinicopathological staging and molecular risk data.
- Case examples illustrating decision-making for active surveillance, minimalist therapy, and systemic treatments.
Main Results:
- The framework provides a structured approach to compare risks, benefits, and patient preferences.
- Demonstrates effective application in managing low-risk papillary thyroid cancer via active surveillance.
- Highlights utility in guiding minimalist therapy for low- and intermediate-risk disease and systemic therapies for advanced cancer.
Conclusions:
- The proposed framework supports personalized thyroid cancer management.
- It aids in achieving informed consensus among clinicians and patients.
- Dynamic risk stratification is key to optimizing therapeutic decision-making throughout the patient's journey.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:24Graves Disease II: Pathophysiology
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Goiter
Goiter refers to an abnormal enlargement of the thyroid gland that may appear as a diffuse goiter (uniform enlargement) or nodular (single or multiple nodules). Functionally, it is classified as nontoxic (normal/low hormone levels) or toxic (excess hormone production).PathophysiologyDiffuse thyroid enlargement typically results from prolonged stimulation by thyroid-stimulating hormone (TSH) or TSH-like agents, commonly seen in hypothyroidism or iodine deficiency. In contrast, in hyperthyroid...